NDAORALTABLET
Approved
Feb 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
4/8 — Partial
BUMEX (bumetanide) by Bausch Health is clinical pharmacology bumex is a loop diuretic with a rapid onset and short duration of action. First approved in 1983.
Drug data last refreshed 17h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BUMEX (bumetanide) is a loop diuretic that works by inhibiting sodium and chloride reabsorption in the ascending limb of the loop of Henle, with potency approximately 40 times that of furosemide. It has rapid onset (30–60 minutes oral; minutes IV) and short duration (4–6 hours), making it suitable for acute and chronic fluid overload management. Bumetanide also exhibits proximal tubule activity and increases potassium and uric acid excretion in a dose-dependent manner.
LOE Approaching
LOE-approaching product with moderate competitive pressure (score: 30); brand team likely focused on lifecycle defense and cost optimization rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Bumex is a loop diuretic with a rapid onset and short duration of action. Pharmacological and clinical studies have shown that 1 mg Bumex has a diuretic potency equivalent to approximately 40 mg furosemide. The major site of Bumex action is the ascending limb of the loop of…
Worked on BUMEX at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.